A practical reference on GHRH analogue: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2025-11-18 and is reviewed periodically as new material appears.
CJC-1295 is a synthetic peptide designed as a long-acting analogue of growth hormone-releasing hormone (GHRH). Its structure derives from the first 29 amino acids of native GHRH, a fragment often called GRF(1-29). Four substitutions were introduced to slow enzymatic breakdown and extend activity relative to the natural sequence. The compound was developed by ConjuChem as part of a broader effort to improve the pharmacokinetic profile of peptide hormones. It is studied in laboratory and clinical research settings rather than appearing as a naturally occurring substance.
Two related forms circulate in technical discussion under the same family name. The original version carries a drug affinity complex (DAC) that binds covalently to serum albumin after administration, and this linkage substantially extends circulation time. A second form, frequently written as modified GRF(1-29) or CJC-1295 without DAC, lacks that linker and clears much faster. The naming is a frequent source of confusion because the shorthand CJC-1295 can refer to either form depending on the source. Reports sometimes fail to specify which variant was studied.
CJC-1295 is the name used for a synthetic peptide modeled on growth hormone-releasing hormone, the hypothalamic signal that prompts the pituitary to release growth hormone. The compound was described by a Canadian drug discovery company in the mid-2000s as a long-acting research tool. Two closely related molecules share the name in practice: one carries a drug affinity complex, or DAC, group, and one does not. The distinction matters because the two behave differently in circulation.
The peptide backbone corresponds to GRF(1-29), the first 29 residues of native growth hormone-releasing hormone, which retains most of the receptor-activating activity of the full-length molecule. Four substitutions distinguish the analog from the natural sequence: D-alanine at position 2, glutamine at position 8, alanine at position 15, and leucine at position 27. These changes slow cleavage by dipeptidyl peptidase IV, the enzyme that degrades native hormone in plasma within minutes. The outcome is improved enzymatic stability combined with a still brief residence time when no additional modification is present.
Naming in this area is inconsistent, and readers should treat product labels with care. In much of the literature and in vendor catalogs, the unqualified term refers to the albumin-binding version, while the version lacking the DAC group appears as modified GRF(1-29), mod GRF(1-29), or the same name with a without-DAC qualifier. Because one abbreviation has been applied to both materials, the only reliable way to identify a sample is to check the stated sequence and the presence of the linker.
| Property | Value | Notes |
|---|---|---|
| Molecular weight (no linker) | ~3.37 kDa | Calculated from peptide sequence |
| Molecular weight (with linker) | ~3.65 kDa | Includes albumin-binding moiety |
| Appearance | White to off-white powder | Typically lyophilized |
| Solubility | Soluble in water | Also dissolves in aqueous buffers |
| Common synonyms | Modified GRF(1-29), DAC:GRF | Usage varies by source |
CJC-1295 is a synthetic peptide belonging to the growth hormone-releasing hormone analog family. It comprises twenty-nine amino acid residues derived from the N-terminal region of natural GHRH. The molecule incorporates several non-natural substitutions that increase resistance to enzymatic degradation. These modifications extend its activity compared with the native hormone fragment. Researchers use it to study pituitary growth hormone secretion in laboratory and clinical settings. This compound is distinct from native GHRH in its stability profile.
Two principal forms appear in the literature and in research supply. One carries a drug affinity complex, a maleimide-based group that forms a covalent bond with circulating albumin. This linkage slows clearance and produces a long-lasting elevation of peptide levels. The other form lacks that group and is often labeled MOD GRF(1-29). It has a much shorter circulation time. Both variants retain the same core receptor-binding sequence. Reported half-lives differ substantially between the two.
CJC-1295 is a synthetic peptide modeled on growth hormone-releasing hormone, the hypothalamic signal that prompts the pituitary to release growth hormone. Its sequence corresponds to the first twenty-nine residues of human GHRH, with four substitutions that slow enzymatic breakdown. Early descriptions placed the compound in research on growth hormone deficiency and related conditions, and later literature groups it with the long-acting GHRH analogs. The name appears in both laboratory and popular fitness writing, where it sometimes labels chemically different peptides.
Two related peptides circulate under the CJC-1295 label, and they differ mainly in how long they persist in circulation. The version carrying a drug affinity complex includes a maleimidopropionic acid linker that forms a covalent bond with serum albumin. The other version, usually written as modified GRF(1-29) or tetrasubstituted GRF(1-29), lacks that linker and is cleared quickly. Mixing the two produces inconsistent readings of published half-life values, because the linker rather than the receptor-facing sequence drives most of the difference.
CJC-1295 belongs to a class of synthetic peptides modeled on growth hormone releasing hormone, a forty-four amino acid signal produced by the hypothalamus. The compound is built from the first twenty-nine residues of the natural sequence, with four substitutions introduced at positions 2, 8, 15 and 27. These changes were designed to slow enzymatic breakdown while preserving receptor activation. The result is a peptide that is shorter than native GHRH and considerably more resistant to ordinary clearance pathways in circulation.
Two related forms appear under the CJC-1295 name. The simpler analogue, commonly written as modified GRF(1-29), carries the four substitutions but no additional conjugation. The second form attaches a maleimidopropionic acid linker to a lysine residue, a modification frequently called the drug affinity complex. That linker reacts with the free thiol on serum albumin to form a covalent bond. Because albumin has a long residence time in blood, the conjugated peptide stays in circulation far longer than the unconjugated analogue.
Characterization of this peptide relies on a small set of routine techniques. Reversed-phase high-performance liquid chromatography separates the target from truncated or oxidized by-products and yields a purity estimate when paired with ultraviolet detection near 214 nanometers. Mass spectrometry, either electrospray coupled to liquid chromatography or matrix-assisted laser desorption, confirms that the observed mass matches the value calculated for the expected sequence. Amino acid analysis, and enzymatic digestion followed by fragment mapping, are used when the sequence itself rather than the mass requires verification.
Stability depends heavily on physical state. A lyophilized powder kept dry, desiccated, and shielded from light typically holds its integrity for months to years at minus twenty degrees Celsius, and longer at minus eighty. Once dissolved, the peptide becomes far more vulnerable, since peptide bond hydrolysis, oxidation of susceptible residues, and aggregation all proceed faster in solution. Buffers near neutral pH are generally gentler than strongly acidic or alkaline conditions. Repeated freeze-thaw cycles and exposure to air-liquid interfaces during vigorous mixing cause losses that are easy to overlook.
In June 2015, Chipotle began test marketing a pork and chicken chorizo-type sausage as a new protein option at selected locations in the Kansas City area. Some food writers have expressed their health related concerns over the protein's relatively high sodium content since a 4-ounce (110 g) serving contains 293 calories and 803 milligrams of sodium while the American Heart Association's recommended daily amount is less than 1,500 milligrams of sodium. In contrast, the protein options with next highest sodium contents are Barbacoa with 530 milligrams and sofritas with 555 milligrams. An earlier version of the Mexican sausage was tested in Denver and New York City in 2011, but that test was terminated when that version of the sausage was perceived as looking too greasy. Chorizo was discontinued in September 2017 but was returned to the menu in the following year for a limited time. In July 2020, Chipotle began test marketing a cauliflower rice option at 55 locations in Colorado and Wisconsin. In August 2021, Chipotle began testing a company-made vegan chorizo made with pea protein. The vegan chorizo (now called plant-based chorizo) was subsequently released nation-wide as a limited-time only item on January 3, 2022, before being removed on March 4, 2022. Chipotle accepts fax orders, and in 2005 the company added the ability to order online from their website. For both online and fax orders, customers proceed to the front of the line to pay for pre-ordered food.
Although overall yields are comparatively low, Lower Saxony is also an important supplier of crude oil in the European Union. Mineral products still mined today include iron. Radioactive waste is frequently transported in the area to the city of Salzgitter, for the deep geological repository Schacht Konrad and between Schacht Asse II in the Wolfenbüttel district and Lindwedel and Höfer. Manufacturing is another large part of the regional economy. Despite decades of gradual downsizing and restructuring, the carmaker Volkswagen with its five production plants within the state's borders still remains the single biggest private-sector employer, its world headquarters in Wolfsburg. Due to the Volkswagen Law, which has recently been ruled illegal by the European Union's high court, the state of Lower Saxony is still the second-largest shareholder, owning 20.3% of the company. Thanks to the importance of car manufacturing in Lower Saxony, a thriving supply industry is centred around its regional focal points. Other mainstays of the Lower Saxon industrial sector include aviation (the region of Stade is called CFK-Valley), shipbuilding (such as Meyer Werft), biotechnology, and steel. Medicine plays a major role; Hanover and Göttingen have two large University Medical Schools and hospitals, and Otto Bock in Duderstadt is the largest producer of prosthetics and associated componentry in the world. The service sector has gained importance following the demise of manufacturing in the 1970s and 1980s.
The creation of URLs that will not change with time is the fundamental method of preventing link rot. Preventive planning has been championed by Tim Berners-Lee and other web pioneers. Berners-Lee recommended designing URIs to avoid details likely to change, such as authorship, subject matter, file extension, software mechanism, or access status. Strategies pertaining to the authorship of links include:
Sources: en.wikipedia.org
== History == In 1938, the Clinical Maternity Hospital No.3 of Yerevan was established. The current building has been operational since 1964. In 2001, the maternity hospital was transformed into the Shengavit Medical Center with a share belonging to the Yerevan municipality. In 2002, the ownership of the hospital became the property of the staff and it was reorganized into a multi-disciplinary clinical-diagnostic institution.
== Further reading == Muir T. W.; Sondhi D.; Cole P. A. (1998). "Expressed protein ligation: A general method for protein engineering". Proc. Natl. Acad. Sci. USA. 95 (12): 6705–6710. Bibcode:1998PNAS...95.6705M. doi:10.1073/pnas.95.12.6705. PMC 22605. PMID 9618476. Nilsson B. L.; Soellner M. B.; Raines R. T. (2005). "Chemical synthesis of proteins". Annu. Rev. Biophys. Biomol. Struct. 34: 91–118. doi:10.1146/annurev.biophys.34.040204.144700. PMC 2845543. PMID 15869385. Kent S. B. H. (2009). "Total chemical synthesis of proteins". Chemical Society Reviews. 38 (2): 338–351. doi:10.1039/B700141J. PMID 19169452. S2CID 5432012. Conibear A. C.; Watson E. E.; Payne R. J.; Becker C. F. W. (2018). "Native chemical ligation in protein synthesis and semi-synthesis". Chemical Society Reviews. 47 (24): 9046–9068. doi:10.1039/c8cs00573g. hdl:2123/22610. PMID 30418441.
== Clinical significance == Deletions and mutations in this gene are associated with supravalvular aortic stenosis (SVAS) and the autosomal dominant cutis laxa. Other associated defects in elastin include Marfan syndrome, emphysema caused by α1-antitrypsin deficiency, atherosclerosis, Buschke–Ollendorff syndrome, Menkes syndrome, pseudoxanthoma elasticum, and Williams syndrome.
Sources: en.wikipedia.org
==== Eyes ==== Rattlesnake eyes, which contain many rod cells, are well adapted to nocturnal use. Rattlesnakes, though, are not exclusively nocturnal, and their vision is more acute during daylight conditions. Rattlesnakes also possess cone cells, which means they are capable of some form of color vision. The rattlesnake eye lacks a fovea, making vision of sharply defined images impossible. Instead, they mostly rely on the perception of movement. Rattlesnake eyes are capable of horizontal rotation, but they do not appear to move their eyeballs to follow moving objects.
Liu Wenhui entered the Xikang area with around ten to twenty thousand troops of the 24th Army at his disposal, equipped with automatic weapons, mortars, and artillery. The size and strength of Liu's remaining forces, even in this diminished state, gave him much authority in dealing with local elites and in pacifying the province. To strengthen control over the local tusi of Kham, Liu ordered from 1932 onwards that all local tribal soldiers be integrated directly into the 24th Army, a measure that reportedly maintained peace in the region.
The risk information seeking and processing (RISP) model analyzes social implications that affect attitudes and decision making pertaining to clinical trials. People who hold a higher stake or interest in the treatment provided in a clinical trial showed a greater likelihood of seeking information about clinical trials. Cancer patients reported more optimistic attitudes towards clinical trials than the general population. Having a more optimistic outlook on clinical trials also leads to greater likelihood of enrolling.
Sources: en.wikipedia.org
No. It is a synthetic analogue modeled on the first 29 residues of human GHRH. The substitutions and any linker are laboratory modifications rather than features of the endogenous peptide.
Early development used the albumin-binding form, and a shorter variant was later discussed under the same label. Because the two differ in half-life and handling, ambiguity arises whenever a source omits the variant designation.
The compound derives from that fragment but is not identical to it. The parent fragment lacks the stabilizing substitutions, so its degradation rate and duration of action differ noticeably.
No. It is a laboratory-made analog of growth hormone-releasing hormone. The natural hormone is a 44-residue peptide, while the analog is built on a shorter 29-residue fragment.